Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era

Background: tixagevimab/cilgavimab, distributed under the name “Evusheld”, was the first available pre-exposure prophylaxis for COVID-19 other than vaccination. It received an EUA from the FDA after sufficient trial data showed efficacy in preventing SARS-CoV-2 infections and subsequent severe disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ntanasis-Stathopoulos, Ioannis, Filippatos, Charalampos, Gavriatopoulou, Maria, Malandrakis, Panagiotis, Eleutherakis-Papaiakovou, Evangelos, Spiliopoulou, Vassiliki, Syrigou, Rodanthi-Eleni, Theodorakakou, Foteini, Fotiou, Despina, Migkou, Magdalini, Roussou, Maria, Kastritis, Efstathios, Dimopoulos, Meletios Athanasios, Terpos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529256/
https://www.ncbi.nlm.nih.gov/pubmed/37754319
http://dx.doi.org/10.3390/diseases11030123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529256/
https://www.ncbi.nlm.nih.gov/pubmed/37754319
http://dx.doi.org/10.3390/diseases11030123

Ejemplares similares